Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Mastocytosis 3Pancreatic Neoplasms 2Recurrence 1Pruritus 1Piebaldism 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1Mastocytosis, Systemic 1Gastrointestinal Stromal Tumors 1Gastro-intestinal Stromal Tumours 1Gastro Intestinal Stromal Tumor 1Colorectal Cancer Metastatic 1Blushing 1

Interventions

Imatinib Mesylate 41Sunitinib 17nilotinib 12regorafenib 10ripretinib 6avapritinib 6Leucovorin 3Ipilimumab 3Gemcitabine 3Dasatinib 3CTLA-4 Antigen 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2Paclitaxel 2Oxaliplatin 2Midazolam 2Irinotecan 2Fluorouracil 2Floxuridine 2Erlotinib Hydrochloride 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2Biopsy, Fine-Needle 2Bevacizumab 2vatalanib 1umbralisib 1trametinib 1tinostamustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Stromal Tumors × masitinib × Clear all
NCT01694277 2020-12-08

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

AB Science

Phase 3 Completed
258 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡